PUBLISHER: IMARC | PRODUCT CODE: 1986435
PUBLISHER: IMARC | PRODUCT CODE: 1986435
The global drug-eluting stents market size reached USD 9.2 Billion in 2025. Looking forward, the market is expected to reach USD 14.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.03% during 2026-2034. The increasing prevalence of cardiovascular diseases is propelling the market.
Implementation of Next-Generation Drugs
The next generation of drug-eluting stents uses advanced medications, such as biolimus and zotarolimus, which have higher efficacy in preventing restenosis while reducing adverse effects, making these stents more useful for a wider variety of patients. For example, in May 2024, Abbott announced the launch of XIENCE Sierra Everolimus (drug) eluting coronary stent system in India. It is a CE-marked and one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. This is leading to the drug-eluting stents market growth.
Expanded Use in Peripheral Artery Disease
Drug-eluting stents are being increasingly utilized to treat peripheral arterial disease (PAD), moving beyond coronary applications. This trend reflects stents' growing use in treating blockages in arteries beyond the heart. In April 2024, Cook Medical received a contract to supply implantable devices to hospitals run by the U.S. Department of Defense (DoD). The company would provide its Zilver PTX drug-eluting peripheral stent, Zenith aortic endograft, and other implantable devices. This is expanding the drug-eluting stents market share.
Increasing Focus on Complex Lesions
Drug-eluting stents are in high demand for treating complicated coronary lesions such as bifurcation and multi-vessel disease. These advanced stents are designed to handle complex anatomical issues with more precision. In June 2024, Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System received Breakthrough Device Designation from the FDA. This bioadaptive implant aims to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.
Among these, polymer free coating holds the largest share of the drug-eluting stents market
Polymer free coating is intended to minimize inflammation and promote healing. These coatings improve medication delivery while eliminating the problems associated with polymers, resulting in better patient outcomes during cardiovascular treatments. This is elevating the drug-eluting stents market revenue.
The drug-eluting stents market overview highlights that sirolimus reduces cell development to avoid arterial narrowing, while paclitaxel inhibits cell division, resulting in better blood flow. Zotarolimus enhances healing while causing less adverse effects, and everolimus has been shown to reduce re-narrowing over time. Biolimus, a biodegradable alternative, promotes vascular recovery, providing a variety of therapy options in the market.
Cobalt-chromium currently holds the largest drug-eluting stents market demand
Cobalt-chromium stents are well-known for their long-lasting, flexible, and biocompatible design. These stents have a sturdy construction but allow for thinner struts, which improves vessel support and reduces problems during cardiovascular treatments. This is elevating the drug-eluting stents market statistics.
The 1st generation drug-eluting stents used basic drug coatings to minimize restenosis. The 2nd generation increased safety by improving biocompatibility and using thinner struts. The 3rd generation focused on biodegradable polymers to improve healing, while the 4th generation uses polymer-free coatings to promote speedier recovery and reduce inflammation. Each generation represents advances in safety, efficacy, and patient outcomes.
Currently, coronary artery disease holds the largest share of the drug-eluting stents market recent price
The market largely focuses on coronary artery disease by releasing medications that prevent restenosis. These stents help to maintain artery patency, improve blood flow, and reduce the need for repeat treatments in patients with blocked or narrowed arteries.
Among these, hospitals currently hold the largest share of the market
Hospitals are the primary end users in this market, as these devices are commonly utilized in cardiovascular surgeries to treat coronary artery disease. These stents are used in hospitals to improve patient outcomes, lower restenosis, and reduce the need for recurrent treatments. This represents one of the drug-eluting stents market recent opportunities.
North America currently dominates the drug-eluting stents market outlook
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America exhibits a clear dominance in the market. This can be attributed to the enhanced healthcare infrastructure, a high prevalence of cardiovascular illnesses, and the growing adoption of cutting-edge stent technology. The region's focus on reducing coronary artery disease promotes demand for these devices.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major drug-eluting stents market companies have also been provided. Some of the key players in the market include:
()